Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
- Status
- UNKNOWN
- Phase
- PHASE3
Clinical Trials Related to HER2-positive Breast Cancer
Related studies linked through entity extraction aliases.
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.
- Status
- COMPLETED
- Phase
- N/A
HER2-directed Biosimilar in Breast Cancer: Real World ePRO
- Status
- COMPLETED
- Phase
- N/A
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Screening Brain MRIs in Stage IV Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
- Status
- UNKNOWN
- Phase
- N/A
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
- Status
- UNKNOWN
- Phase
- PHASE4